Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Set To Launch Xience Prime Stents In India; Says Solvay's Products Will Broaden Focus

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As part of its strategy to focus sharply on India, illustrated by two acquisitions that expand its therapeutic presence significantly, Abbott is set to bring to India its next-generation drug-eluting stent Xience Prime by the fourth quarter of 2009

You may also be interested in...



Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two

Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies

Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two

Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies

Abbott Plays On Diverse Offering As It Cruises Higher Than Most In India

MUMBAI - Size matters and Abbott Laboratories amply demonstrated its significance when last year it emerged as the dark horse and acquired the India prescriptions business of Piramal Healthcare Ltd. at a steep valuation of $3.72 billion, or 9 times the sales and 31 times the pre-tax profit

Latest News
See All
UsernamePublicRestriction

Register

SC070101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel